ONCOLOGY PIPELINE LEADS TO NEW EISAI INC.

Eisai Inc. today announces plans for a new pharmaceutical production and formulation research and development facility for parenteral -- or intravenous -- oncology treatments. Eisai has a number of drugs in development for patients with cancer. "Oncology is one of Eisai's long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs," said Lonnel Coats, President and COO, Eisai Inc. "Our plans for the new facility in RTP demonstrate Eisai's global commitment to oncology and patients around the world."

dBusinessNews (http://triangle.dbusinessnews.com/shownews.php?newsid=64000&type_news=latest)